I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional
(outside the UK and Australia):

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

WOC 2022

-
Coming soon
10:00 AM
Duration 10mins Virtual
Faricimab in Neovascular Age-Related Macular Degeneration: 48-Week Results by Dosing Cohort in the Phase 3 TENAYA/LUCERNE Trials
Michels S, Cheung G, Lai T, Quezada Ruiz C, Silverman D, Ives J, Swaminathan B, Lin H, Willis J, Kotecha A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 5mins Virtual
Angiopoietin (Ang)-2 Signaling and Vascular Stability (VS) With Faricimab (FAR) in Diabetic Macular Edema (DME)
Fraser-Bell S, Jouseen A, Maturi R, Westenskow PD, Willlis JR, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:00 AM
Duration 10mins Virtual
Key Pearls of the Refill-Exchange Procedure for the Port Delivery System With Ranibizumab (PDS)
Fung A, Khanani A, Singh N, Barteselli G, Callaway N, Patel S, Jaycock P, Menezes A, Malhotra V

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 10mins Virtual
Multinational Patient Experience with Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
Layana AG, Giocanti A, Holekamp N, Jackson T, Kertes P, Viola F, Chi G, Mirt M, Barbier V, Lewis H, De Palma A, Gentile B

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
02:45 PM
Duration 5mins Virtual
View the WOC 2022 symposium on "Expert clinical insights: Targeting the Ang/Tie2 pathway for the management of retinal diseases"
Guymer R, Lai T, Koh A, Cheung G, London N

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:30 PM
Duration 10mins Virtual
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Results From the Phase 3 TENAYA and LUCERNE Trials
Hwang DK, Holz F, Khanani A, Singh R, Silverman D, Swaminathan B, Patel V, Lin H, Willis J, Kotecha A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 10mins Virtual
Personalized Treatment Interval (PTI) Dosing Dynamics in the Phase 3 YOSEMITE/RHINE Trials of Faricimab in Diabetic Macular Edema
Tan CS, Jaffe GJ, Gerendas BS, Chakravarthy U, Goldberg RA, Korobelnik JF, Abreu F, Jain N, Tang Y, Camino A, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 10mins Virtual
VOYAGER: A Real-world Study of the Port Delivery System With Ranibizumab (PDS) and Faricimab (FAR) in nAMD and DME
Koh A, Bailey C, Bengus M, Chaikitmongkol V, Chakravarthy U, Chaudhary V, Chi G, Finger R, Gallego-Pinazo R, Glittenberg C, Lovestram-Adrian M, Parravano M, Luna Pinto J, Scheidl S, Schmitz-Valckenberg M, Sheth V, Souied E, Guymer R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:00 PM
Duration 10mins Virtual
Key Clinical Pearls for Evaluating Surgical Candidates, and Patient Preference, for the Port Delivery System With Ranibizumab
Koh A, Figueroa M, Holekamp N, Bobbala A, Callaway N, DeGraaf S, Menezes A, Heinrich D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
05:15 PM
Duration 10mins Virtual
Efficacy, Durability and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Murata T, Wells JA, Baumal C, Danzig C, Schlottmann P, Lin H, Mohan S, Silverman D, Tang Y, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 10mins Virtual
Faricimab for Macular Edema Due to Retinal Vein Occlusion: Rationale and Design of the Phase 3 BALATON and COMINO Trials
Mehta H, Danzig C, Paris L, Lin H, Jain N, Abreu F, Haskova Z, Hattenbach LO

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 10mins Virtual
Faricimab in Neovascular Age-Related Macular Degeneration: Efficacy, Safety, and Durability Through Week 48 in TENAYA and LUCERNE
Guymer R, Cheung CMG, Margaron P, Quezada Ruiz C, Silverman D, Ives J, Basu K, Souverain A, Yang M, Lin H, Willis J, Kotecha A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 10mins Virtual
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Patient Case Profiles From the Phase 3 TENAYA and LUCERNE Trials
Pearce I, Figueroa M, Silverman D, Swaminathan B, Patel V, Lin H, Willis J, Kotecha A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar